@article{5f822ed5fdfe44dca496516a4ecf092d,
title = "Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris",
keywords = "bullous disorders, disease control, pemphigus",
author = "Murrell, {D. F.} and A. Patsatsi and P. Stavropoulos and S. Baum and T. Zeeli and Kern, {J. S.} and R. Sinclair and A. Neale and P. Arora and Sugerman, {P. B.} and G. Shi and Werth, {V. P.} and F. Caux and P. Joly and {on behalf of the BELIEVE Trial Investigators}",
note = "Funding Information: We thank the patients who participated in the trial, their caregivers, the trial investigators, members of the BELIEVE-PV data and safety monitoring board and adjudication committee, and members of the BELIEVE-PV trial team. We thank Dr Steve Gourlay for input on the initial study design, Fiona Liu of SCiAN Services Inc. for statistical support, and Owen Hagino for content review. The authors received medical writing and editorial support in the preparation of this manuscript from Julie Kern, PhD, CMPP and Mihaela Marina, PhD of Second City Science LLC, sponsored by Principia Biopharma Inc, a Sanofi Company. This study was sponsored by Principia Biopharma Inc, a Sanofi Company. Funding Information: F. Caux reports medical writing support from Second City Science funded by Principia Biopharma; grants or contracts for his institution from Argenx, Regeneron, and Roche; and participation on a data safety monitoring board or advisory board from Principia Biopharma. Funding Information: This study was sponsored by Principia Biopharma Inc, a Sanofi Company. ",
year = "2022",
month = oct,
doi = "10.1111/jdv.18318",
language = "English",
volume = "36",
pages = "852--855",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "10",
}
